ClinicalTrials.gg
CompletedNCT05431153Updated Apr 8, 2024Results posted

A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants

A Phase 1 interventional study of Single dose of PF-07104091 as Tablet Formulation A (Treatment A) and Single dose of PF-07104091 as Tablet Formulation B (Treatment B) in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-08.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

This is a single dose crossover pharmacokinetic (pharmacokinetics helps in understanding how the drug is changed and eliminated from the body after a participant takes it) study in healthy participants. The study consists of 5 treatments, and each participant will be randomized to receive 4 of the treatments in separate periods in a specific sequence. Each treatment consists of a single dose of PF-07104091 and the treatments differ by tablet formulation and/or whether the dose is to be given under fasted or fed conditions. Plasma pharmacokinetics of PF-07104091 will be assessed following each dose to determine the effect of tablet formulation and fed condition on the relative bioavailability of PF-07104091.

02

Conditions studied

  • Healthy

Keywords

  • PF-07104091
  • Food-effect
  • Relative Bioavailability
  • Pharmacokinetics
  • Cyclin-Dependent Kinase 2 (CDK2) inhibitor
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, vital signs, and standard 12 lead ECGs.
  • Body-Mass Index () of 17.5 to 30.5 kg/m2; and a total body weight of >50 kg (110 lb).
  • Written evidence of a personally signed and dated document (ICD) indicating that the participant has been informed of all pertinent aspects of the study.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures

Exclusion criteria

Exclusion Criteria:

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
  • History of (HIV) infection, , or ; positive testing for HIV, hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAB) or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic (eg, contact with positive case, residence, or travel to an area with high incidence) that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  • A positive urine drug test.
  • History of sensitivity to heparin or heparin induced thrombocytopenia.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    PF-07104091 Sequence 1

    Participants randomized to Sequence 1 will receive Treatments A, B, C, and D in Periods 1 through 4, respectively in the form of tablets by mouth.

    Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)

  • Experimental
    PF-07104091 Sequence 2

    Participants randomized to Sequence 2 will receive Treatments B, C, A, and D in Periods 1 through 4, respectively in the form of tablets by mouth.

    Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)

  • Experimental
    PF-07104091 Sequence 3

    Participants randomized to Sequence 3 will receive Treatments C, A, B, and D in Periods 1 through 4, respectively in the form of tablets by mouth.

    Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation D (Treatment D)

  • Experimental
    PF-07104091 Sequence 4

    Participants randomized to Sequence 4 will receive Treatments A, B, C, and E in Periods 1 through 4, respectively in the form of tablets by mouth.

    Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)

  • Experimental
    PF-07104091 Sequence 5

    Participants randomized to Sequence 5 will receive Treatments B, C, A, and E in Periods 1 through 4, respectively in the form of tablets by mouth.

    Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)

  • Experimental
    PF-07104091 Sequence 6

    Participants randomized to Sequence 6 will receive Treatments C, A, B, and E in Periods 1 through 4, respectively in the form of tablets by mouth.

    Drug: Single dose of PF-07104091 as Tablet Formulation A (Treatment A) · Drug: Single dose of PF-07104091 as Tablet Formulation B (Treatment B) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment C) · Drug: Single dose of PF-07104091 as Tablet Formulation C (Treatment E)

Interventions

  • DrugSingle dose of PF-07104091 as Tablet Formulation A (Treatment A)

    A single dose of PF-07104091 as Tablet Formulation A administered under fasting conditions.

    Also known as: Tablet Formulation A, Fasted

  • DrugSingle dose of PF-07104091 as Tablet Formulation B (Treatment B)

    A single dose of PF-07104091 as Tablet Formulation B administered under fasting conditions.

    Also known as: Tablet Formulation B, Fasted

  • DrugSingle dose of PF-07104091 as Tablet Formulation C (Treatment C)

    A single dose of PF-07104091 as Tablet Formulation C administered under fasting conditions.

    Also known as: Tablet Formulation C, Fasted

  • DrugSingle dose of PF-07104091 as Tablet Formulation D (Treatment D)

    A single dose of PF-07104091 as Tablet Formulation D administered under fasting conditions.

    Also known as: Tablet Formulation D, Fasted

  • DrugSingle dose of PF-07104091 as Tablet Formulation C (Treatment E)

    A single dose of PF-07104091 as Tablet Formulation C administered under fed conditions.

    Also known as: Tablet Formulation C, Fed

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C

    AUCinf was calculated as AUClast + (Clast/kel) where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve.

    Time frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

  2. Maximum Observed Plasma Concentration (Cmax) of PF-07104091 for Treatment A, B and C

    Cmax was maximum observed concentration. Cmax was observed directly from data.

    Time frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

Secondary outcomes

  1. AUCinf of PF-07104091 for Treatment C, D and E

    AUCinf was calculated as AUClast + (Clast/kel) where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve.

    Time frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

  2. Cmax of PF-07104091 for Treatment C, D and E

    Cmax was maximum observed concentration. Cmax was observed directly from data.

    Time frame: Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose

  3. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, other important medical events. TEAEs were defined as events that occurred after start of treatment.

    Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)

  4. Number of Participants With Laboratory Test Abnormalities

    Clinical hematology parameters included: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes; chemistry parameters included: blood urea nitrogen and creatinine, cystatin C and estimated glomerular filtration rate, glucose (fasting), calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, urinalysis parameters included: local dipstick: potential of hydrogen (pH), glucose, protein, blood, ketones, nitrites, leukocyte esterase. Number of participants with abnormal findings are presented in this outcome measure.

    Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)

  5. Number of Participants With Clinically Meaningful Findings in Electrocardiogram (ECG) Assessments

    A 12-lead ECG was performed. Clinically meaningful findings in ECG assessments were based on the investigator's judgment.

    Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)

  6. Number of Participants With Clinically Meaningful Findings in Vital Signs

    Vital signs were measured with the participant's arm supported at the level of the heart after approximately 5 minutes of rest. Vital signs parameters included: diastolic and systolic blood pressure, respiratory rate, pulse rate, and temperature. Number of participants with clinically meaningful findings in any vital sign parameter were reported. Clinically meaningful findings were based on the investigator's judgment.

    Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)

  7. Number of Participants With Clinically Meaningful Findings in Physical Examination Assessments

    A complete physical examination included at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination included at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant-reported symptoms. Clinically significant findings were defined according to investigator's assessment.

    Time frame: From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)

07

Results

Posted Apr 8, 2024

Participant flow

Treatment Period 1 (Day 1)
Participant flow — Treatment Period 1 (Day 1)
MilestoneTreatment Sequence ABCDTreatment Sequence BCADTreatment Sequence CABDTreatment Sequence ABCETreatment Sequence BCAETreatment Sequence CABE
Started555555
Completed555545
Not completed000010
Withdrew: Withdrawal by subject000010
Washout Period 1 (5 Days)
Participant flow — Washout Period 1 (5 Days)
MilestoneTreatment Sequence ABCDTreatment Sequence BCADTreatment Sequence CABDTreatment Sequence ABCETreatment Sequence BCAETreatment Sequence CABE
Started555545
Completed555545
Not completed000000
Treatment Period 2 (Day 1)
Participant flow — Treatment Period 2 (Day 1)
MilestoneTreatment Sequence ABCDTreatment Sequence BCADTreatment Sequence CABDTreatment Sequence ABCETreatment Sequence BCAETreatment Sequence CABE
Started555545
Completed555545
Not completed000000
Washout Period 2 (5 Days)
Participant flow — Washout Period 2 (5 Days)
MilestoneTreatment Sequence ABCDTreatment Sequence BCADTreatment Sequence CABDTreatment Sequence ABCETreatment Sequence BCAETreatment Sequence CABE
Started555545
Completed555545
Not completed000000
Treatment Period 3 (Day 1)
Participant flow — Treatment Period 3 (Day 1)
MilestoneTreatment Sequence ABCDTreatment Sequence BCADTreatment Sequence CABDTreatment Sequence ABCETreatment Sequence BCAETreatment Sequence CABE
Started555545
Completed555545
Not completed000000
Washout Period 3 (5 Days)
Participant flow — Washout Period 3 (5 Days)
MilestoneTreatment Sequence ABCDTreatment Sequence BCADTreatment Sequence CABDTreatment Sequence ABCETreatment Sequence BCAETreatment Sequence CABE
Started555545
Completed555545
Not completed000000
Treatment Period 4 (Day 1)
Participant flow — Treatment Period 4 (Day 1)
MilestoneTreatment Sequence ABCDTreatment Sequence BCADTreatment Sequence CABDTreatment Sequence ABCETreatment Sequence BCAETreatment Sequence CABE
Started555545
Completed555545
Not completed000000

Outcome measures

PrimaryArea Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C

AUCinf was calculated as AUClast + (Clast/kel) where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve.

Time frame:
Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · Nanograms*hour per milliliter
Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C
Nanograms*hour per milliliterTreatment A: PF-07104091 Tablet Formulation A (Fasted)Treatment B: PF-07104091 Tablet Formulation B (Fasted)Treatment C: PF-07104091 Tablet Formulation C (Fasted)
Area Under the Plasma-Concentration Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of PF-07104091 for Treatment A, B, and C10920 ± 3410720 ± 2811200 ± 32
Statistical analysis
  • Treatment A: PF-07104091 Tablet Formulation A (Fasted) vs Treatment B: PF-07104091 Tablet Formulation B (Fasted) · Ratio of adjusted geometric means: 98.83 · 90% CI 94.00 to 103.91Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
  • Treatment A: PF-07104091 Tablet Formulation A (Fasted) vs Treatment C: PF-07104091 Tablet Formulation C (Fasted) · Ratio of adjusted geometric means: 98.02 · 90% CI 93.88 to 102.35Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
  • Treatment B: PF-07104091 Tablet Formulation B (Fasted) vs Treatment C: PF-07104091 Tablet Formulation C (Fasted) · Ratio of adjusted geometric means: 98.51 · 90% CI 91.79 to 105.73Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
PrimaryMaximum Observed Plasma Concentration (Cmax) of PF-07104091 for Treatment A, B and C

Cmax was maximum observed concentration. Cmax was observed directly from data.

Time frame:
Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · Nanograms per milliliter
Maximum Observed Plasma Concentration (Cmax) of PF-07104091 for Treatment A, B and C
Nanograms per milliliterTreatment A: PF-07104091 Tablet Formulation A (Fasted)Treatment B: PF-07104091 Tablet Formulation B (Fasted)Treatment C: PF-07104091 Tablet Formulation C (Fasted)
Maximum Observed Plasma Concentration (Cmax) of PF-07104091 for Treatment A, B and C1531 ± 311490 ± 281415 ± 34
Statistical analysis
  • Treatment A: PF-07104091 Tablet Formulation A (Fasted) vs Treatment B: PF-07104091 Tablet Formulation B (Fasted) · Ratio of adjusted geometric means: 96.35 · 90% CI 87.48 to 106.12Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
  • Treatment A: PF-07104091 Tablet Formulation A (Fasted) vs Treatment C: PF-07104091 Tablet Formulation C (Fasted) · Ratio of adjusted geometric means: 93.47 · 90% CI 85.65 to 102.00Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
  • Treatment B: PF-07104091 Tablet Formulation B (Fasted) vs Treatment C: PF-07104091 Tablet Formulation C (Fasted) · Ratio of adjusted geometric means: 98.01 · 90% CI 89.86 to 106.90Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
SecondaryAUCinf of PF-07104091 for Treatment C, D and E

AUCinf was calculated as AUClast + (Clast/kel) where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log linear concentration-time curve.

Time frame:
Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · Nanograms*hour per milliliter
AUCinf of PF-07104091 for Treatment C, D and E
Nanograms*hour per milliliterTreatment C: PF-07104091 Tablet Formulation C (Fasted)Treatment D: PF-07104091 Tablet Formulation D (Fasted)Treatment E: PF-07104091 Tablet Formulation C (Fed)
AUCinf of PF-07104091 for Treatment C, D and E11200 ± 3212850 ± 3210500 ± 24
Statistical analysis
  • Treatment C: PF-07104091 Tablet Formulation C (Fasted) vs Treatment D: PF-07104091 Tablet Formulation D (Fasted) · Ratio of adjusted geometric means: 111.52 · 90% CI 99.55 to 124.93Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
  • Treatment C: PF-07104091 Tablet Formulation C (Fasted) vs Treatment E: PF-07104091 Tablet Formulation C (Fed) · Ratio of adjusted geometric means: 98.38 · 90% CI 90.68 to 106.73Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
SecondaryCmax of PF-07104091 for Treatment C, D and E

Cmax was maximum observed concentration. Cmax was observed directly from data.

Time frame:
Predose, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours post-dose
Reported as:
Geometric mean · Nanograms per milliliter
Cmax of PF-07104091 for Treatment C, D and E
Nanograms per milliliterTreatment C: PF-07104091 Tablet Formulation (Fasted)Treatment D: PF-07104091 Tablet Formulation D (Fasted)Treatment E: PF-07104091 Tablet Formulation C (Fed)
Cmax of PF-07104091 for Treatment C, D and E1415 ± 341498 ± 361193 ± 36
Statistical analysis
  • Treatment C: PF-07104091 Tablet Formulation (Fasted) vs Treatment D: PF-07104091 Tablet Formulation D (Fasted) · Ratio of adjusted geometric means: 111.52 · 90% CI 96.46 to 128.93Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
  • Treatment C: PF-07104091 Tablet Formulation (Fasted) vs Treatment E: PF-07104091 Tablet Formulation C (Fed) · Ratio of adjusted geometric means: 81.39 · 90% CI 75.06 to 88.26Values were back-transformed from the log scale. The model was a mixed effect model with sequence, period and treatment as fixed effects and participant within sequence as a random effect.
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the following criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic, other important medical events. TEAEs were defined as events that occurred after start of treatment.

Time frame:
From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsTreatment A: PF-07104091 Tablet Formulation A (Fasted)Treatment B: PF-07104091 Tablet Formulation B (Fasted)Treatment C: PF-07104091 Tablet Formulation C (Fasted)Treatment D: PF-07104091 Tablet Formulation D (Fasted)Treatment E: PF-07104091 Tablet Formulation C (Fed)
TEAEs21191772
Serious TEAEs00000
SecondaryNumber of Participants With Laboratory Test Abnormalities

Clinical hematology parameters included: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes; chemistry parameters included: blood urea nitrogen and creatinine, cystatin C and estimated glomerular filtration rate, glucose (fasting), calcium, sodium, potassium, chloride, total bicarbonate, aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein, urinalysis parameters included: local dipstick: potential of hydrogen (pH), glucose, protein, blood, ketones, nitrites, leukocyte esterase. Number of participants with abnormal findings are presented in this outcome measure.

Time frame:
From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Test Abnormalities
ParticipantsTreatment A: PF-07104091 Tablet Formulation A (Fasted)Treatment B: PF-07104091 Tablet Formulation B (Fasted)Treatment C: PF-07104091 Tablet Formulation C (Fasted)Treatment D: PF-07104091 Tablet Formulation D (Fasted)Treatment E: PF-07104091 Tablet Formulation C (Fed)
Number of Participants With Laboratory Test Abnormalities00131
SecondaryNumber of Participants With Clinically Meaningful Findings in Electrocardiogram (ECG) Assessments

A 12-lead ECG was performed. Clinically meaningful findings in ECG assessments were based on the investigator's judgment.

Time frame:
From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Findings in Electrocardiogram (ECG) Assessments
ParticipantsTreatment A: PF-07104091 Tablet Formulation A (Fasted)Treatment B: PF-07104091 Tablet Formulation B (Fasted)Treatment C: PF-07104091 Tablet Formulation C (Fasted)Treatment D: PF-07104091 Tablet Formulation D (Fasted)Treatment E: PF-07104091 Tablet Formulation C (Fed)
Number of Participants With Clinically Meaningful Findings in Electrocardiogram (ECG) Assessments00000
SecondaryNumber of Participants With Clinically Meaningful Findings in Vital Signs

Vital signs were measured with the participant's arm supported at the level of the heart after approximately 5 minutes of rest. Vital signs parameters included: diastolic and systolic blood pressure, respiratory rate, pulse rate, and temperature. Number of participants with clinically meaningful findings in any vital sign parameter were reported. Clinically meaningful findings were based on the investigator's judgment.

Time frame:
From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Findings in Vital Signs
ParticipantsTreatment A: PF-07104091 Tablet Formulation A (Fasted)Treatment B: PF-07104091 Tablet Formulation B (Fasted)Treatment C: PF-07104091 Tablet Formulation C (Fasted)Treatment D: PF-07104091 Tablet Formulation D (Fasted)Treatment E: PF-07104091 Tablet Formulation C (Fed)
Number of Participants With Clinically Meaningful Findings in Vital Signs00000
SecondaryNumber of Participants With Clinically Meaningful Findings in Physical Examination Assessments

A complete physical examination included at a minimum, head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, and gastrointestinal, musculoskeletal, and neurological systems. A brief physical examination included at a minimum, assessments of general appearance, the respiratory and cardiovascular systems, and participant-reported symptoms. Clinically significant findings were defined according to investigator's assessment.

Time frame:
From start of study treatment until 35 days after last dose of study treatment (Up to Day 54)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Findings in Physical Examination Assessments
ParticipantsTreatment A: PF-07104091 Tablet Formulation A (Fasted)Treatment B: PF-07104091 Tablet Formulation B (Fasted)Treatment C: PF-07104091 Tablet Formulation C (Fasted)Treatment D: PF-07104091 Tablet Formulation D (Fasted)Treatment E: PF-07104091 Tablet Formulation C (Fed)
Number of Participants With Clinically Meaningful Findings in Physical Examination Assessments00000

Adverse events

Collected over From start of study treatment until 35 days after last dose of study treatment (Up to Day 54). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A: PF-07104091 Tablet Formulation A (Fasted)0/29 (0%)0/29 (0%)21/29 (72.4%)
Treatment B: PF-07104091 Tablet Formulation B (Fasted)0/30 (0%)0/30 (0%)18/30 (60%)
Treatment C: PF-07104091 Tablet Formulation C (Fasted)0/29 (0%)0/29 (0%)17/29 (58.6%)
Treatment D: PF-07104091 Tablet Formulation D (Fasted)0/15 (0%)0/15 (0%)7/15 (46.7%)
Treatment E: PF-07104091 Tablet Formulation C (Fed)0/14 (0%)0/14 (0%)2/14 (14.3%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTreatment A: PF-07104091 Tablet Formulation A (Fasted)Treatment B: PF-07104091 Tablet Formulation B (Fasted)Treatment C: PF-07104091 Tablet Formulation C (Fasted)Treatment D: PF-07104091 Tablet Formulation D (Fasted)Treatment E: PF-07104091 Tablet Formulation C (Fed)
NauseaGastrointestinal disorders18/2014/3013/294/151/14
VomitingGastrointestinal disorders6/297/303/293/150/14
DiarrhoeaGastrointestinal disorders5/294/305/291/150/14
HeadacheNervous system disorders3/295/303/292/150/14
DyspepsiaGastrointestinal disorders0/291/300/292/150/14
FatigueGeneral disorders1/291/303/291/150/14
DizzinessNervous system disorders3/291/303/291/151/14
PainGeneral disorders0/290/300/290/151/14
Appetite disorderMetabolism and nutrition disorders0/200/300/290/151/14
Rash erythematousSkin and subcutaneous tissue disorders0/290/301/290/151/14

Baseline characteristics

All enrolled participants were analyzed.

Age, Continuous
Age, Continuous(Years)Treatment Sequence ABCD+BCAD+CABDTreatment Sequence ABCE+BCAE+CABETotal
Mean41.9 ± 13.0440.3 ± 13.0641.1 ± 12.85
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Sequence ABCD+BCAD+CABDTreatment Sequence ABCE+BCAE+CABETotal
Female000
Male151530
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Sequence ABCD+BCAD+CABDTreatment Sequence ABCE+BCAE+CABETotal
Hispanic or Latino257
Not Hispanic or Latino131023
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Sequence ABCD+BCAD+CABDTreatment Sequence ABCE+BCAE+CABETotal
American Indian or Alaska Native000
Asian303
Native Hawaiian or Other Pacific Islander000
Black or African American6814
White6713
More than one race000
Unknown or Not Reported000
08

Study locations

1 site
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Oct 2022, 4 months.

Results were first posted in Apr 2024, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2022
First posted
Jun 24, 2022
StartActual
Jun 10, 2022
Primary completionActual
Oct 17, 2022
CompletionActual
Oct 17, 2022
Results first posted
Apr 8, 2024
Last update
Apr 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05431153
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jun 24, 2022
Start date
Jun 10, 2022
Primary completion
Oct 17, 2022
Completion
Oct 17, 2022
Results posted
Apr 8, 2024
Last update
Apr 8, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion